Ovid Therapeutics (OVID)
(Delayed Data from NSDQ)
$1.17 USD
+0.11 (10.38%)
Updated Sep 19, 2024 04:00 PM ET
After-Market: $1.16 -0.01 (-0.85%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Brokerage Reports
0 items in cart
Ovid Therapeutics [OVID]
Reports for Purchase
Showing records 1 - 15 ( 15 total )
Company: Ovid Therapeutics
Industry: Medical - Biomedical and Genetics
Reduced Expenses, Approaching Catalysts; 2Q24 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Ovid Therapeutics
Industry: Medical - Biomedical and Genetics
Company: Ovid Therapeutics
Industry: Medical - Biomedical and Genetics
OV329 Data Could Bring Interesting Near-Term Catalyst
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Ovid Therapeutics
Industry: Medical - Biomedical and Genetics
Scientific Advisory Board Expanded; OV329 Validation; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Ovid Therapeutics
Industry: Medical - Biomedical and Genetics
OV888 Yields Positive Phase 1 Data; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Ovid Therapeutics
Industry: Medical - Biomedical and Genetics
OV888 Update Arrives As Anticipated, Moving To Phase 2
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Ovid Therapeutics
Industry: Medical - Biomedical and Genetics
Restructuring Not Unexpected, Looking Ahead To OV329
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Ovid Therapeutics
Industry: Medical - Biomedical and Genetics
Soticlestat Misses Mark; Pipeline Retains Value; Lowering PT to $3
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Ovid Therapeutics
Industry: Medical - Biomedical and Genetics
Taking Out Soticlestat, But Sticking With OVID and OV329
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Ovid Therapeutics
Industry: Medical - Biomedical and Genetics
Soticlestat Pivotal Data Approaching; 1Q24 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Ovid Therapeutics
Industry: Medical - Biomedical and Genetics
Why OVID''s Worth A Look -- Near-Term Catalysts For One
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Ovid Therapeutics
Industry: Medical - Biomedical and Genetics
Revolutionizing Treatment for CNS Disorders; Initiating at Buy and $9 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Ovid Therapeutics
Industry: Medical - Biomedical and Genetics
Company: Ovid Therapeutics
Industry: Medical - Biomedical and Genetics
We are initiating coverage with an Outperform rating and $8 target.
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Ovid Therapeutics
Industry: Medical - Biomedical and Genetics
|